Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Exelixis, Inc., and Prometheus Laboratories Inc.
Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based
Clinical decision making in the setting of metastatic renal cell carcinoma (RCC) has dramatically changed in the past few years. Recent and pending approvals of new agents and combinations, as well as expanded indications, have raised questions about how rational treatment planning can be used to match the optimal strategy to the patient. At the same time, accumulating real-world experience with newer agents and emerging trial data continue to refine state-of-the-art care in RCC. Most recently, the frontline, metastatic, clear cell RCC setting has evolved with the introduction of new options and the prospect of administering initial therapy to patients who have already received an adjuvant tyrosine kinase inhibitor strategy. This activity is designed to address your key questions related to RCC management via discussion of data and real-world patient cases by a multidisciplinary faculty of internationally recognized experts in RCC. Adverse event management and future directions in the field are also addressed and considered throughout the program in the context of the program theme, to help you individualize patient care. Foremost, this program aims to provide you with cutting-edge practical guidance that can be applied immediately to your clinical practices.
This case-based educational activity features video interviews with renowned experts in RCC who share their perspectives on evidence-based state-of-the-art management strategies designed to meet the specific needs of oncologists who treat patients with genitourinary (GU) cancers. Throughout the activity, the faculty lead participants through an in-depth exploration of the latest data and their clinical implications.
Instructions for This Activity and Receiving Credit
This educational program is directed toward medical oncologists interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC are also invited to participate.
At the conclusion of this activity, you should be better prepared to:
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Jerome and Nancy Kohlberg Professor, Medicine, Harvard Medical School
Disclosure: Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, GlaxoSmithKline, Merck, Novartis, Peloton Therapeutics, Pfizer, Roche, Tracon Pharmaceuticals, Eisai; Consultant: AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean Pharma, Eisai, Foundation Medicine Inc, Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton Therapeutics, Pfizer, Prometheus Laboratories, Corvus Pharmaceuticals, Ipsen Group.
Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Institut Gustave Roussy, Villejuif
Disclosure: Consultant: Bristol-Myers Squibb, Pfizer, Novartis, Ipsen Group, Roche
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure: Grant/Research Support: Peloton Therapeutics, Bristol-Myers Squibb, Argos Therapeutics, Exelixis, Merck; Consultant: Pfizer, CB Therapeutics.
Thomas Powles, MBBS, MRCP, MD
Clinical Professor of Genitourinary Oncology
Experimental Cancer Medicine Centre
Barts Cancer Institute
Barts and The London School of Medicine
Disclosure: Grant/Research Support: AstraZeneca, Roche; Speaker’s Bureau: AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Exelixis, Ipsen Group, Eisai.
Brian I. Rini, MD, FACP
Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Disclosure: Grant/Research Support: Pfizer, Merck, Genentech; Consultant: Merck, Pfizer.
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Sep 29, 2018
Sep 29, 2018
Sep 29, 2018
September 29, 2018
New York, New York
September 29, 2018
Sep 30, 2018
Sep 30, 2018